MBX Biosciences (MBX) Accumulated Expenses (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Accumulated Expenses data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 90.14% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (up 90.14% YoY), and the FY2025 full-year result was $12.3 million, up 431.24% from the prior year.
• Accumulated Expenses declined to $2.3 million in Q1 2026, from $12.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $12.3 million in Q4 2025 to a low of $1.2 million in Q1 2025.
• A 4-year average of $4.6 million and a median of $2.4 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses slipped 2.43% in 2024 and jumped 431.24% in 2025, its largest moves.
• Tracing MBX's Accumulated Expenses over 4 years: stood at $2.4 million in 2023, then dropped by 2.43% to $2.3 million in 2024, then jumped by 431.24% to $12.3 million in 2025, then sank by 81.1% to $2.3 million in 2026.
• Business Quant data shows MBX's Accumulated Expenses at $2.3 million in Q1 2026, $12.3 million in Q4 2025, and $8.1 million in Q3 2025.